A snapshot of pharma’s early experiences of EMA’s new definitive, centralized registration system.
Contrary to anecdotal evidence, the majority of Clinical & Quality leads at Pharma, Biotech and CROs are largely positive about the one-stop portal, which promises to make Europe a more attractive and cohesive market in which to conduct trials.
In August 2022, at roughly the half way point between CTR go-live and the mandatory date for compliance with CTIS for new studies, we engaged Censuswide to capture the early experiences and views of 400 relevant Director+/relevant Functional Heads in Pharma, Biotech and CRO companies (breaking down into 100 representatives per market in the UK, Germany, Switzerland, and the US).
